SEQUENCE LISTING

<110> Abbott Laboratories
      Henkin, Jack
      Haviv, Fortuna
      Bradley, Michael F.
      Kalvin, Douglas M.
      Schneider, Andrew J.

<120> PEPTIDE ANTIANGIOGENIC DRUGS

<130> 6356.US.C1

<140> Not yet assigned
<141> 2004-01-23

<150> US 09/447,226
<151> 1999-11-22

<150> US 09/316,888
<151> 1999-05-21

<150> US 60/126,546
<151> 1999-03-26

<150> US 60/086,536
<151> 1998-05-28

<160> 6

<170> FastSEQ for Windows Version 4.0

<210> 1
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> Antiangiogenetic Peptide

<221> VARIANT
<222> (1)...(1)
<223> Xaa = Ala, Asn, Cit, Gln, Glu, NEtGly, Met,
      N-methylalanyl, Pro, pyro-Glu, Sar, Ser, or Thr at
      position 1

<221> VARIANT
<222> (2)...(2)
<223> Xaa = Ala, Asn, Asp, Gln, Glu, Leu, Met, Phe, Pro,
      or Ser at position 2

<221> VARIANT
<222> (3)...(3)
<223> Xaa = Ala, Asn, Cit, Cha, Chg, Gln, Glu, Gly, Ile,
      Leu, Met, Nva, Phe, Ser, tButylgly, Thr, Val, Pen,
      or Cys at position 3

<221> VARIANT

```
<222> (4)...(4)
<223> Xaa = alloIle, Gly, Ile, Pro, or dehydroleu at
      position 4

<221> VARIANT
<222> (5)...(5)
<223> Xaa = Ala, 3-Pal, 1-Nal, 2-Nal, allo-threonyl,
      allylgly, Gln, Gly, His, Hser, Ile, Lys(Ac), Met,
      Nva, Octylgly, Orn, Phe(4-CH2OH), Pro, Ser, Thr,
      Trp, Tyr, Pen, or Cys at position 5

<221> VARIANT
<222> (6)...(6)
<223> Xaa = Ala, 1-Nal, 2-Nal, 3-Pal, Abu, allylgly,
      Arg, Asn, Asp, Cit, Cha, Gln, Glu, Gly, His,
      Homoala, Hle, Hser, Ile, Leu, Lys(Ac), Lys(Isp),
      at position 6

<221> VARIANT
<222> (6)...(6)
<223> 6 Cont'd:
      Xaa = Met(O2), Met(O), Met, Nor, Nva, Octygly,
      Phe, Phe(4-CONH2), Propargylgly, Ser, Thr, Trp,
      Tyr, Val, Pen, or Cys at position 6

<221> VARIANT
<222> (7)...(7)
<223> Xaa = Ala, Allylgly, Asn, Cit, Chg, Gln, Gly,
      Hser, Ile, alloIle, Leu, Lys(Ac), Met, 1-Nal,
      2-Nal, Nva, Phe, Pro, Ser, tButylgly, Trp, Tyr,
      Val, Pen, or Cys at position 7

<221> VARIANT
<222> (8)...(8)
<223> Xaa = Aminopyprimidinobutanoyl, Ala(3-guanidino),
      Ala(3-pyrrolidinylamidino), Ala[4-Pip(N-amidino)],
      Arg, arginyl(NGNG'diethyl), Cit, Cha(4-NIsp),
      Gly[4-pip(N-amido)],  at position 8

<221> VARIANT
<222> (8)...(8)
<223> 8 Cont'd:
      Xaa = His, Harg, Lys, Lys(Ile), Lys(Nic), Norarg,
      Orn(Isp), Orn(Nic), Orn(2-imidazo),
      Phe(4-CH2NHIsp), Phe(4-guanidino), or Phe(4-NIsp)
      at position 8

<221> VARIANT
<222> (9)...(9)
<223> Xaa = Abu, Aib, homoprolyl, hydroxyprolyl, Ile,
      Leu, Phe, Pro, Ser, tButylgly, Tic, Thr, or Val at
      position 9

<221> VARIANT
<222> (10)...(10)
<223> Xaa = azaglycylamide, glycylamide,
      glycylethylamide, sarcosylamide, serylamide at
      position 10

<400> 1
```

```
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
 1               5               10
```

```
<210> 2
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> Antiangiogenetic peptide

<221> VARIANT
<222> (1)...(1)
<223> Xaa = sarcosyl at position 1

<221> VARIANT
<222> (6)...(6)
<223> Xaa = norvaline at position 6

<400> 2
Xaa Gly Val Ile Thr Xaa Ile Arg Pro
 1               5


<210> 3
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> Antiangiogenetic peptide

<221> VARIANT
<222> (1)...(1)
<223> Xaa = sarcosyl at position 1

<221> VARIANT
<222> (6)...(6)
<223> Xaa = norvaline at position 6

<400> 3
Xaa Gly Val Gly Thr Xaa Ile Arg Pro
 1               5


<210> 4
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> Antiangiogenetic peptide

<221> VARIANT
<222> (1)...(1)
<223> Xaa = sarcosyl at position 1

<221> VARIANT
<222> (4)...(4)
```

<223> Xaa = allo-isoleucyl at position 4

<221> VARIANT
<222> (6)...(6)
<223> Xaa = norvaline at position 6

<400> 4
Xaa Gly Val Xaa Thr Xaa Ile Arg Pro
 1   5

<210> 5
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> Antiangiogenetic peptide

<221> VARIANT
<222> (1)...(1)
<223> Xaa = sarcosyl at position 1

<221> VARIANT
<222> (4)...(4)
<223> Xaa = dehydroleucyl at position 4

<221> VARIANT
<222> (6)...(6)
<223> Xaa = norvaline at position 6

<400> 5
Xaa Gly Val Xaa Thr Xaa Ile Arg Pro
 1   5

<210> 6
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> Antiangiogenetic Peptide

<221> VARIANT
<222> (1)...(1)
<223> Xaa = R-(CH2)n-C(O)- where R is N-acetylamino at
      position 1

<221> VARIANT
<222> (2)...(2)
<223> Xaa = Sar at position 2

<221> VARIANT
<222> (5)...(5)
<223> Xaa = AlloIle, dehydroleu, Gly, Ile or Pro at
      position 5

<221> VARIANT
<222> (6)...(6)

<223> Xaa = Ala, 3-Pal, 1-Nal, 2-Nal, allo-threonyl,
      allylgly, Gln, Gly, His, Hser, Ile, Lys(Ac), Met,
      Nva, Octylgly, Orn, Phe(3-CH2OH), Pro, Ser, Thr,
      Trp, Tyr, Pen or Cys at position 6

<221> VARIANT
<222> (7)...(7)
<223> Xaa = Ala, 1-Nal, 2-Nal, 3-Pal, Abu, allylgly,
      Arg, Asn, Asp, Cit, Cha, Gln, Glu, Gly, His,
      Homoala, Hle, Hser, Ile, Leu, Lys(Ac), Lys(Isp),
      at position 7

<221> VARIANT
<222> (7)...(7)
<223> 7 Con'td:
      Xaa = Met(O2), Met(O), Met, Nor, Nva, Octygly,
      Phe, Phe(4-CONH2), Proparglygly, Ser, Thr, Trp,
      Tyr, Val, Pen, or Cys at position 7

<221> VARIANT
<222> (11)...(11)
<223> Xaa = Azaglycylamide, glycylamide,
      glycylethylamide, sarcosylamide, serylamide at
      position 11

<400> 6
Xaa Xaa Gly Val Xaa Xaa Xaa Ile Arg Pro Xaa
 1   5   10